Grifols (NASDAQ:GRFS) Upgraded at Zacks Research

Posted by on Jul 9th, 2026

Grifols (NASDAQ:GRFS – Get Free Report) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

GRFS has been the topic of several other reports. Wall Street Zen downgraded Grifols from a “buy” rating to a “hold” rating in a research report on Monday, May 18th. Weiss Ratings downgraded shares of Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $10.00.

Read Our Latest Stock Analysis on Grifols

Grifols Price Performance

GRFS stock opened at $7.31 on Tuesday. The stock’s 50 day moving average price is $7.64 and its 200 day moving average price is $8.36. The firm has a market cap of $4.98 billion, a P/E ratio of 38.47, a PEG ratio of 0.28 and a beta of 0.67. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.85 and a current ratio of 2.47. Grifols has a 1 year low of $6.96 and a 1 year high of $11.14.

Institutional Investors Weigh In On Grifols

A number of institutional investors have recently bought and sold shares of the stock. Allworth Financial LP raised its stake in Grifols by 15.7% during the fourth quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 1,096 shares during the period. Cerity Partners LLC raised its position in shares of Grifols by 6.3% in the 4th quarter. Cerity Partners LLC now owns 19,121 shares of the biotechnology company’s stock worth $179,000 after buying an additional 1,131 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Grifols by 25.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 1,212 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Grifols by 10.1% in the 1st quarter. Bank of New York Mellon Corp now owns 16,419 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 1,511 shares during the period. Finally, Versant Capital Management Inc increased its position in Grifols by 36.0% during the 2nd quarter. Versant Capital Management Inc now owns 6,958 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,842 shares in the last quarter.

Grifols Company Profile

(Get Free Report)

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.

Featured Articles

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.